Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Collage of Thomas Layton, Lynn Williams and Osaid Alser.

The International Dupuytren Award 2021 for Basic Research was shared between two researchers from the Kennedy Institute of Rheumatology at NDORMS. Lynn Williams was recognised for her paper "Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300" published in PNAS, and Thomas Layton for "Cellular census of human fibrosis defines functionally distinct stromal cell types and states" which appeared in Nature Communications.

The award for Best Clinical Paper award was won by Osaid Alser for the work he completed as MSc by Research student at NDORMS before graduating and moving to Harvard. His paper "Serious complications and risk of re-operation after Dupuytren’s disease surgery: a population-based cohort study of 121,488 patients in England" appeared in Nature Scientific Reports.

Dominic Furniss, who co-supervised Osaid and Thomas, said: “My congratulations go to our researchers who have been recognised for their work by the International Dupuytren Society. The research explores the underlying causes of Dupuyren’s disease and helps us move towards improving treatment for this disabling condition.”

The International Dupuytren Award recognises exceptional scientific publications on research or clinical treatment of Dupuytren and/or Ledderhose disease. 

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.